Propafenone
Propafenone is a medicine taken by mouth, sold as propafenone hydrochloride, that the US label describes as an antiarrhythmic drug, a medicine for heart rhythm problems. The label read, a generic tablet label, lists three uses: to prolong the time to recurrence of paroxysmal atrial fibrillation or flutter that causes disabling symptoms, and of paroxysmal supraventricular tachycardia that causes disabling symptoms, in patients without structural heart disease; and to treat documented ventricular arrhythmias, such as sustained ventricular tachycardia, that a physician judges to be life-threatening. The label says the effect of propafenone on mortality has not been determined. It carries a boxed warning on mortality.
Also called Rythmol
- Drug
- In this atlas
Overview
Technical summary
RxNorm ingredient 8754 (propafenone); the label names the salt propafenone hydrochloride (RxNorm 203135, UNII 33XCH0HOCD, a broad match to the ingredient). MeSH descriptor D011405 is Propafenone. RxClass lists the FDA established pharmacologic class Antiarrhythmic. The label read is the ANI Pharmaceuticals, Inc. generic propafenone hydrochloride tablet label, application ANDA076550, effective 2025-09-12 in openFDA; propafenone hydrochloride is the only active ingredient. The brands Rythmol (NDA019151) and Rythmol SR (NDA021416) are listed in Drugs@FDA with marketing status Discontinued, and the openFDA name search for Rythmol returned no record. The extended-release capsule labels, whose indication is limited to symptomatic atrial fibrillation, were not used, and neither were the other openFDA propafenone labels. This page records label indications, the class, the mechanism sentence and the boxed warning on mortality only: no trial result and no dose is given.
About this drug
- Level
- Substance
- Mechanism
- The label says propafenone is a Class 1C antiarrhythmic drug with local anesthetic effects and a direct stabilizing action on myocardial membranes.
Classification codes
-
33XCH0HOCDPropafenone hydrochloride
Claims and evidence
Context Patients with paroxysmal atrial fibrillation or flutter, paroxysmal supraventricular tachycardia, or life-threatening ventricular arrhythmias, as described in the US label of propafenone hydrochloride tablets
- Recipient
- Recipient not specified
- Population
- Patients described in the indications section of the label: patients without structural heart disease who have paroxysmal atrial fibrillation or flutter, or paroxysmal supraventricular tachycardia, with disabling symptoms, and patients with documented life-threatening ventricular arrhythmias. The passages read do not state an age range.
- Care setting
- Prescription medicine, as described in the US label
- Geography
- United States (label of the US Food and Drug Administration)
- Life stage
- Not stated in the label passages read
- Gestational age
- Not reported
- Postnatal age
- Not reported
- Follow-up
- Not applicable (label statement)
Eligibility: 3 inclusion criteria; exclusion criteria not stated
- Included
- Patients without structural heart disease with paroxysmal atrial fibrillation or flutter associated with disabling symptoms
- Patients without structural heart disease with paroxysmal supraventricular tachycardia associated with disabling symptoms
- Patients with documented ventricular arrhythmias, such as sustained ventricular tachycardia, that are life-threatening in the physician's judgment
- Excluded
- None stated
The US label of propafenone hydrochloride tablets (ANI Pharmaceuticals, Inc., application ANDA076550; the version dated 2025-09-12 in openFDA) describes propafenone as an antiarrhythmic. It lists prolonging the time to recurrence of paroxysmal atrial fibrillation or flutter, and of paroxysmal supraventricular tachycardia, each associated with disabling symptoms in patients without structural heart disease, and treatment of documented ventricular arrhythmias, such as sustained ventricular tachycardia, that in the judgment of the physician are life-threatening. It states that the effect of propafenone on mortality has not been determined.
Applies to Recipient not specified Patients with paroxysmal atrial fibrillation or flutter, paroxysmal supraventricular tachycardia, or life-threatening ventricular arrhythmias, as described in the US label of propafenone hydrochloride tablets
- Certainty method
- Not assessed
- Limitations
- This claim records what one US generic tablet label says the medicine is indicated for. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. The label also lists usage considerations (for example, that use in permanent atrial fibrillation has not been evaluated); those are the label's statements and are not repeated as advice. Extended-release capsule labels, which state a narrower atrial fibrillation indication, were not read. Contraindications, other warnings, interactions, the label's pediatric statement and dosing were not recorded. openFDA lists other propafenone labels with different dates, and its own disclaimer says not to rely on it for decisions about medical care.
- Last checked
- 2026-11-18
- Next evidence check due
- Not scheduled
Sources and citations (7)
-
- Locator
- results[0].indications_and_usage[0], Highlights statement
- How it applies
- Label passage quoted in the research quote table (LB-04).
- Retrieved
- Source effective date
- 2025-09-12
- Source state
- Current
- Version fingerprint
f5314b4941e7937612a4798d433c561a8dc9396a491e4f825c700804c5905e9d- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
-
- Locator
- results[0].indications_and_usage[0], indications statement
- How it applies
- Label passage quoted in the research quote table (LB-05).
- Retrieved
- Source effective date
- 2025-09-12
- Source state
- Current
- Version fingerprint
f5314b4941e7937612a4798d433c561a8dc9396a491e4f825c700804c5905e9d- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
-
- Locator
- results[0].indications_and_usage[0], first bullet
- How it applies
- Label passage quoted in the research quote table (LB-06).
- Retrieved
- Source effective date
- 2025-09-12
- Source state
- Current
- Version fingerprint
f5314b4941e7937612a4798d433c561a8dc9396a491e4f825c700804c5905e9d- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
-
- Locator
- results[0].indications_and_usage[0], second bullet
- How it applies
- Label passage quoted in the research quote table (LB-07).
- Retrieved
- Source effective date
- 2025-09-12
- Source state
- Current
- Version fingerprint
f5314b4941e7937612a4798d433c561a8dc9396a491e4f825c700804c5905e9d- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
-
- Locator
- results[0].indications_and_usage[0], third bullet
- How it applies
- Label passage quoted in the research quote table (LB-08).
- Retrieved
- Source effective date
- 2025-09-12
- Source state
- Current
- Version fingerprint
f5314b4941e7937612a4798d433c561a8dc9396a491e4f825c700804c5905e9d- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
-
- Locator
- results[0].indications_and_usage[0], usage considerations
- How it applies
- Label passage quoted in the research quote table (LB-09).
- Retrieved
- Source effective date
- 2025-09-12
- Source state
- Current
- Version fingerprint
f5314b4941e7937612a4798d433c561a8dc9396a491e4f825c700804c5905e9d- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
-
- Locator
- results[0].effective_time
- How it applies
- Effective date of the label text read, 20250912.
- Retrieved
- Source effective date
- 2025-09-12
- Source state
- Current
- Version fingerprint
f5314b4941e7937612a4798d433c561a8dc9396a491e4f825c700804c5905e9d- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
Context Patients with structural heart disease, and the population of the trial known as Cardiac Arrhythmia Suppression Trial (CAST), as described in a US propafenone label boxed warning
- Recipient
- Recipient not specified
- Population
- The warning speaks of subjects with asymptomatic non-life-threatening ventricular arrhythmias after a myocardial infarction (the trial it cites, treated with encainide or flecainide) and of patients with structural heart disease (for any IC antiarrhythmic). The passages read give no age range.
- Care setting
- Prescription medicine, as described in the US label
- Geography
- United States (label of the US Food and Drug Administration)
- Life stage
- Not stated in the label passages read
- Gestational age
- Not reported
- Postnatal age
- Not reported
- Follow-up
- Not applicable (label statement)
Eligibility: 1 inclusion criterion; exclusion criteria not stated
- Included
- Patients with structural heart disease (the group in which the warning says to consider any IC antiarrhythmic a significant proarrhythmic risk)
- Excluded
- None stated
The same US label carries a boxed warning titled mortality. It says that in the trial known as Cardiac Arrhythmia Suppression Trial (CAST) an increased rate of death or reversed cardiac arrest was seen in subjects treated with encainide or flecainide (Class IC antiarrhythmics) compared with placebo, and that it is prudent to consider any IC antiarrhythmic to have a significant proarrhythmic risk when structural heart disease is present.
Applies to Recipient not specified Patients with structural heart disease, and the population of the trial known as Cardiac Arrhythmia Suppression Trial (CAST), as described in a US propafenone label boxed warning
- Certainty method
- Not assessed
- Limitations
- This claim records the title and two statements of the label's boxed warning only. The CAST result was in patients treated with encainide or flecainide, not propafenone; the warning says its applicability to other drugs and populations is uncertain. The trial numbers and the warning's statement on non-life-threatening ventricular arrhythmias are not repeated. Other warnings, contraindications and interactions were not recorded, and no instruction is given. openFDA's own disclaimer says not to rely on it for decisions about medical care.
- Last checked
- 2026-11-18
- Next evidence check due
- Not scheduled
Sources and citations (4)
-
- Locator
- results[0].boxed_warning[0], title
- How it applies
- Label passage quoted in the research quote table (LB-11).
- Retrieved
- Source effective date
- 2025-09-12
- Source state
- Current
- Version fingerprint
f5314b4941e7937612a4798d433c561a8dc9396a491e4f825c700804c5905e9d- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
-
- Locator
- results[0].boxed_warning[0], first bullet
- How it applies
- Label passage quoted in the research quote table (LB-12).
- Retrieved
- Source effective date
- 2025-09-12
- Source state
- Current
- Version fingerprint
f5314b4941e7937612a4798d433c561a8dc9396a491e4f825c700804c5905e9d- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
-
- Locator
- results[0].boxed_warning[0], second bullet
- How it applies
- Label passage quoted in the research quote table (LB-13).
- Retrieved
- Source effective date
- 2025-09-12
- Source state
- Current
- Version fingerprint
f5314b4941e7937612a4798d433c561a8dc9396a491e4f825c700804c5905e9d- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
-
- Locator
- results[0].effective_time
- How it applies
- Effective date of the label text read, 20250912.
- Retrieved
- Source effective date
- 2025-09-12
- Source state
- Current
- Version fingerprint
f5314b4941e7937612a4798d433c561a8dc9396a491e4f825c700804c5905e9d- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
Clinical links
Each link reports what one cited claim says about one population. "Evaluated for" means studied, not shown to work. These links do not show that anything is effective or right for you.
-
Claim, not a settled fact FDA label lists prolonging the time to recurrence of paroxysmal atrial fibrillation or flutter associated with disabling symptoms, in patients without structural heart disease, as an indication: Atrial fibrillation (AF)
Applies to Recipient not specified Patients with paroxysmal atrial fibrillation or flutter, paroxysmal supraventricular tachycardia, or life-threatening ventricular arrhythmias, as described in the US label of propafenone hydrochloride tablets
The US label of propafenone hydrochloride tablets (ANI Pharmaceuticals, Inc., application ANDA076550; the version dated 2025-09-12 in openFDA) describes propafenone as an antiarrhythmic. It lists prolonging the time to recurrence of paroxysmal atrial fibrillation or flutter, and of paroxysmal supraventricular tachycardia, each associated with disabling symptoms in patients without structural heart disease, and treatment of documented ventricular arrhythmias, such as sustained ventricular tachycardia, that in the judgment of the physician are life-threatening. It states that the effect of propafenone on mortality has not been determined.Limitations. This claim records what one US generic tablet label says the medicine is indicated for. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. The label also lists usage considerations (for example, that use in permanent atrial fibrillation has not been evaluated); those are the label's statements and are not repeated as advice. Extended-release capsule labels, which state a narrower atrial fibrillation indication, were not read. Contraindications, other warnings, interactions, the label's pediatric statement and dosing were not recorded. openFDA lists other propafenone labels with different dates, and its own disclaimer says not to rely on it for decisions about medical care.
-
Claim, not a settled fact FDA label lists prolonging the time to recurrence of paroxysmal atrial fibrillation or flutter associated with disabling symptoms, in patients without structural heart disease, as an indication: Atrial flutter
Applies to Recipient not specified Patients with paroxysmal atrial fibrillation or flutter, paroxysmal supraventricular tachycardia, or life-threatening ventricular arrhythmias, as described in the US label of propafenone hydrochloride tablets
The US label of propafenone hydrochloride tablets (ANI Pharmaceuticals, Inc., application ANDA076550; the version dated 2025-09-12 in openFDA) describes propafenone as an antiarrhythmic. It lists prolonging the time to recurrence of paroxysmal atrial fibrillation or flutter, and of paroxysmal supraventricular tachycardia, each associated with disabling symptoms in patients without structural heart disease, and treatment of documented ventricular arrhythmias, such as sustained ventricular tachycardia, that in the judgment of the physician are life-threatening. It states that the effect of propafenone on mortality has not been determined.Limitations. This claim records what one US generic tablet label says the medicine is indicated for. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. The label also lists usage considerations (for example, that use in permanent atrial fibrillation has not been evaluated); those are the label's statements and are not repeated as advice. Extended-release capsule labels, which state a narrower atrial fibrillation indication, were not read. Contraindications, other warnings, interactions, the label's pediatric statement and dosing were not recorded. openFDA lists other propafenone labels with different dates, and its own disclaimer says not to rely on it for decisions about medical care.
-
Claim, not a settled fact FDA label lists prolonging the time to recurrence of paroxysmal supraventricular tachycardia associated with disabling symptoms, in patients without structural heart disease, as an indication: Supraventricular tachycardia
Applies to Recipient not specified Patients with paroxysmal atrial fibrillation or flutter, paroxysmal supraventricular tachycardia, or life-threatening ventricular arrhythmias, as described in the US label of propafenone hydrochloride tablets
The US label of propafenone hydrochloride tablets (ANI Pharmaceuticals, Inc., application ANDA076550; the version dated 2025-09-12 in openFDA) describes propafenone as an antiarrhythmic. It lists prolonging the time to recurrence of paroxysmal atrial fibrillation or flutter, and of paroxysmal supraventricular tachycardia, each associated with disabling symptoms in patients without structural heart disease, and treatment of documented ventricular arrhythmias, such as sustained ventricular tachycardia, that in the judgment of the physician are life-threatening. It states that the effect of propafenone on mortality has not been determined.Limitations. This claim records what one US generic tablet label says the medicine is indicated for. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. The label also lists usage considerations (for example, that use in permanent atrial fibrillation has not been evaluated); those are the label's statements and are not repeated as advice. Extended-release capsule labels, which state a narrower atrial fibrillation indication, were not read. Contraindications, other warnings, interactions, the label's pediatric statement and dosing were not recorded. openFDA lists other propafenone labels with different dates, and its own disclaimer says not to rely on it for decisions about medical care.
-
Claim, not a settled fact FDA label lists treatment of documented life-threatening ventricular arrhythmias, such as sustained ventricular tachycardia, as an indication: Ventricular tachycardia
Applies to Recipient not specified Patients with paroxysmal atrial fibrillation or flutter, paroxysmal supraventricular tachycardia, or life-threatening ventricular arrhythmias, as described in the US label of propafenone hydrochloride tablets
The US label of propafenone hydrochloride tablets (ANI Pharmaceuticals, Inc., application ANDA076550; the version dated 2025-09-12 in openFDA) describes propafenone as an antiarrhythmic. It lists prolonging the time to recurrence of paroxysmal atrial fibrillation or flutter, and of paroxysmal supraventricular tachycardia, each associated with disabling symptoms in patients without structural heart disease, and treatment of documented ventricular arrhythmias, such as sustained ventricular tachycardia, that in the judgment of the physician are life-threatening. It states that the effect of propafenone on mortality has not been determined.Limitations. This claim records what one US generic tablet label says the medicine is indicated for. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. The label also lists usage considerations (for example, that use in permanent atrial fibrillation has not been evaluated); those are the label's statements and are not repeated as advice. Extended-release capsule labels, which state a narrower atrial fibrillation indication, were not read. Contraindications, other warnings, interactions, the label's pediatric statement and dosing were not recorded. openFDA lists other propafenone labels with different dates, and its own disclaimer says not to rely on it for decisions about medical care.
Record details
- Record id
cardio:propafenone- Content hash
c87c3a7d3e40ae10b91135bb12aa7c3a7d86a70002c2787e555b7e7309ef9dd5